TherapeuticsMD Celebrates Recent Listing on NYSE MKT
Executives and guests of TherapeuticsMD, a women's healthcare product company focused on creating and commercializing hormone therapy products targeted exclusively for women, will visit the New York Stock Exchange (NYSE) on Friday, June 14 to commemorate the company's recent listing on NYSE MKT. TherapeuticsMD began trading on NYSE MKT on April 23rd under the ticker symbol TXMD. Rob Finizio, Chief Executive Officer and co-founder, along with members of TherapeuticsMD's leadership team, will ring The Opening Bell® to celebrate this company milestone.
TherapeuticsMD, Inc. is a women's health pharmaceutical company driven to pursue the development and commercialization of advanced hormone replacement therapies. We are currently developing advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. We are evaluating various other potential indications for our hormone technology, including oral contraception, preterm birth, vulvar and vaginal atrophy, and premature ovarian failure. More information is available at www.therapeuticsmd.com. (Source: TherapeuticMD)